文献速递消化道肿瘤放疗放疗物理与技术

多重邻近连接法鉴定局部晚期胰腺癌SBRT预后血清标志物

Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-10-12

经10% FDR校正后,无临床因素或标志物与总生存改善相关;手术切除、IL-8、CA 19-9和MMP-1为潜在候选。

要点

  • SBRT前血清36种标志物经10% FDR校正后均未与生存相关
  • 手术切除、IL-8、CA 19-9和MMP-1为未来研究潜在候选

核心结论

  • 经10% FDR校正后,本队列中无临床因素或血清标志物与局部晚期胰腺癌患者生存改善相关。
  • 手术切除、IL-8、CA 19-9和MMP-1被列为未来血清标志物研究的潜在候选。

研究设计与样本

  • SBRT前采集血清,用邻近连接法定量36种胰腺癌候选血清标志物,值经对数转换后行Cox回归,Benjamini-Hochberg法控制FDR为10%。

主要发现

  • 经FDR校正后,手术切除(P=.007,校正P=.153)、IL-8(P=.006,校正P=.153)、CA 19-9(P=.031,校正P=.377)和MMP-1(P=.036,校正P=.377)均未达统计学显著。
  • 未发现其他临床因素(包括术前化疗、术后化疗、体能状态和年龄)与生存改善相关。

关键数值与推荐

  • FDR校正阈值为10%。
  • 手术切除P=.007,校正P=.153;IL-8 P=.006,校正P=.153;CA 19-9 P=.031,校正P=.377;MMP-1 P=.036,校正P=.377。

临床怎么用

  • 目前尚无经FDR校正后与生存相关的血清标志物可用于局部晚期胰腺癌SBRT风险分层。
  • IL-8、CA 19-9和MMP-1可作为未来血清标志物研究的候选,暂不推荐临床常规使用。

局限性

  • 采用保守的10% FDR校正,潜在关联未达显著。
  • 结果来自两项前瞻性试验的探索性分析,需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To explore seromarker levels for associations with outcomes in locally advanced pancreatic cancer (LAPC) patients who received chemotherapy and stereotactic body radiation therapy (SBRT). METHODS AND MATERIALS: Serum from LAPC patients in 2 prospective trials of hypofractionated SBRT (5-6.6 Gy × 5) was collected before SBRT. Proximity ligation assay quantified the expression levels of 36 pancreatic cancer-specific candidate seromarkers: Axl, BMP2, CA 125, CA 19-9, CEA, CXCL-1/6/9/10, EGFR, Gas6, Her2, IGF-2, IGFBP-2/3/7, IL-6/6Ra/7/8/12, mesothelin, MMP-1/2/3/7, osteopontin, PDGFRa, PDK1, PF4, RegIV, SPARC, TGF-β, VEGF-A/D, and YKL40. Seromarker values were log transformed owing to log-normal distribution of the values, and Cox regression analysis was performed to assess for any association with overall survival. The Benjamini-Hochberg method was used to control for a false discovery rate (FDR) of only 10%. RESULTS: Sixty-four patients with LAPC were included. No clinical factors (including surgical resection, receipt of pre-SBRT chemotherapy, receipt of post-SBRT chemotherapy, performance status, and age) or potential biomarkers in the panel were associated with improved survival in this cohort after application of the FDR correction. Potential prognostic factors for improved survival for future investigation included surgical resection (P=.007, adjusted P=.153) and the serum expression of IL-8 (P=.006, adjusted P=.153), CA 19-9 (P=.031, adjusted P=.377), and MMP-1 (P=.036, adjusted P=.377). CONCLUSIONS: These data explore the expression of a panel of proteins in pre-SBRT serum of LAPC patients in the context of a conservative FDR correction. None of the clinical factors or expression levels of the serum proteins were found to be associated with survival; however, IL-8, CA 19-9, and MMP-1 were highlighted as possible candidates warranting inclusion in future seromarker studies in the ongoing efforts to identify tools for risk stratification and treatment allocation in LAPC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Rao AD, Liu Y, von Eyben R, et al. Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017. PMID: 29157747. doi:10.1016/j.ijrobp.2017.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。